ATTR-CM Third Quarter ’26 Pubs Update: Expanding Evidence, Real-World Insights & Updated Guidelines on the Role of TTR Stabilization in the DMT Era

Oct 12, 2026 | ATTR

ATTR-CM Second Quarter ’26 Pubs Update: Evolving Evidence, Disease Progression, and the Role of TTR Stabilization in the DMT Era

Jul 6, 2026 | ATTR

Factor XI and the Critical Difference Between Inhibiting Thrombosis and Inhibiting Hemostasis

Oct 27, 2021 | Antithrombotics

2) This series is supported by educational grants from Bayer & AstraZeneca & is intended for healthcare professionals. Faculty disclosures & statement of accreditation at https://t.co/gvXca4G9Xm. Earlier programs, still available for credit, are at...

Management of Hyperkalemia in Patients Treated with RAASi/MRAs

Aug 25, 2021 | HYPERKALEMIA

2) This program is intended for healthcare professionals and is supported by educational grants from AstraZeneca, Bayer, Chiesi, and NovoNordisk. See archived programs, all by expert authors, still available for credit at https://t.co/U6Mo1oSwIh— cardio-met...

Initiating New Anti-thrombotic Therapy into the Treatment Regimen of a Patient with PAD

Mar 11, 2021 | PAD

2) Accredited for 0.5 credits by @academiccme: physicians, nurses, pharmacists! Expert faculty @dlbhattmd. Supported by Abbott, AstraZeneca, Bayer, Chiesi, NovoNordisk. Follow this thread for credit. #cardiotwitter #medtwitter— cardio-met (@cardiomet_CE) March 8, 2021...